See also:
All atrial fibrillation clinical trials
All clinical trials of antithrombotics
All clinical trials of dabigatran 100mg
|
|
RE-LY 110mg subgroup study, 2010
|
|
Treatments
Studied treatment |
dabigatran 110mg daily
|
Control treatment |
warfarin
|
Patients
Patients |
patients with a prior stroke or transient ischemic attack
|
Method and design
Randomized effectives |
NA / NA (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Follow-up duration |
2 y |
Remarks |
sub group ( 20% of the overall study population in RE-LY)
|
Remarks / Comments
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
thrombo-embolic event (cerebral or systemic)
NA / -9
NA / -9
0,85 [0,59;1,22]
TE event or ischemic stroke or systemic embolism
NA / -9
NA / -9
0,85 [0,59;1,22]
Haemmorhagic stroke
NA / -9
NA / -9
0,11 [0,03;0,44]
intracranial hemorrhage
NA / -9
NA / -9
0,20 [0,08;0,48]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Reference(s)
-
1.Diener HC, Connolly S, Ezekowitz MD, et al..
Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY.
American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 195
Pubmed
|
Hubmed
| Fulltext
|